Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : SERB Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
M8 Pharmaceuticals Signs Exclusive Agreement with SERB to Bring Voraxaze® to Latin America
Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : SERB Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further system...
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Inapplicable
November 25, 2021
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.
Product Name : Megludase
Product Type : Enzyme
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Acquisition
Details : BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Undisclosed
February 03, 2021
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Glucarpidase,Methotrexate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : An ongoing arm of the study triggered by the difficult circumstances created by the COVID-19 pandemic is exploring the planned use of Voraxaze® (glucarpidase) to enable high dose MTX treatment of CNSL on an outpatient basis.
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Glucarpidase,Methotrexate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucarpidase,Methotrexate,Rituximab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this study, adult patients with isolated CNSL are treated with rituximab and methotrexate administered for eight cycles. Voraxaze® is given 24 hours following start of each methotrexate infusion.
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Inapplicable
April 23, 2020
Lead Product(s) : Glucarpidase,Methotrexate,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable